Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

BioMarin and n-Lorem Foundation Enter Research Collaboration for ReNU Syndrome Treatment

ByNicholas Jacobus

July 28th 2026

Pharma M&A Roundup: Oak Hill Bio Combines with RACC, Apnimed Plans $150 Million IPO, CORE Biomedicine Secures $21 Million Series A

ByNicholas Jacobus

July 28th 2026

Patrick T. Harker, B.S., M.S., Ph.D., Rowan Distinguished Professor, Professor of Operations, Information and Decisions at the Wharton School of the University of Pennsylvania and Director of Academic Engagement for Penn Washington.

How MBA Graduates Can Break into Competitive Industries in 2026: 4 Practical Steps

ByMichael Wong

July 28th 2026

Operation Trialblazer and Why Clinical Trials are Leaving the US: Q&A with Richard Graham

ByMike Hollan,Dr. Richard Graham

July 28th 2026

Pharmaceutical Executive Daily: FDA Approves Simtriyo

ByNicholas Jacobus

July 27th 2026

Pharmaceutical Executive Digital Edition - January 2010

Articles in this issue

Related Content

BioMarin and n-Lorem Foundation Enter Research Collaboration for ReNU Syndrome Treatment

Pharma M&A Roundup: Oak Hill Bio Combines with RACC, Apnimed Plans $150 Million IPO, CORE Biomedicine Secures $21 Million Series A

How MBA Graduates Can Break into Competitive Industries in 2026: 4 Practical Steps

Operation Trialblazer and Why Clinical Trials are Leaving the US: Q&A with Richard Graham

Pharmaceutical Executive Daily: FDA Approves Simtriyo

Trending on PharmExec

FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients

Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr

Pharmaceutical Executive Daily: FDA Approves Simtriyo

argenx Acquires Forte Biosciences for $2.2 Billion

Where the True Bottlenecks Exist at FDA for Clinical Trials